摘要
目的观察替比夫定(LdT)治疗前后慢性乙型肝炎(CHB)患者HBsAg水平和血清中可溶性E选择素(sE-selectin)含量的变化。方法 107例CHB患者给予口服LdT 600 mg/d治疗,观察治疗前、治疗后第12、24和48周时患者HBsAg水平和血清中sE-selectin含量的变化,并进行相关性分析。结果 CHB患者血清sE-selectin含量明显高于健康对照组(P<0.01)。与治疗前相比,107例患者经LdT治疗后HBsAg水平和血清中sE-selectin含量均明显降低(P<0.01)。相关性分析表明,HBsAg水平和血清sE-selectin含量呈正相关(P<0.01)。结论 LdT可通过降低CHB患者血清中sE-selectin水平,提高免疫功能来抑制HBV复制。
Objective To compare the levels of hepatitis B surface antigen（HBsAg） and serum soluble（s）E-selectin before and after telbivudine（LdT） treatment in patients with chronic hepatitis B（CHB）.Methods One-hundred-and-seven patients with CHB and 82 healthy controls were enrolled in the study.The levels of HBsAg and serum sE-selectin were measured by enzyme-linked immunosorbent assay（ELISA） before and after LdT treatment.The correlation between HBsAg and serum sE-selectin was analyzed by Pearson′s correlation analysis.Results The pre-treatment sE-selectin content of the CHB group was significantly higher than that of the healthy control group（P0.01）.The levels of both HBsAg and sE-selectin were significantly reduced in the CHB group after treatment with LdT（P0.01）.The correlation analysis showed that the HBsAg level was positively correlated with the content of sE-selectin（P0.01）.Conclusion sLdT may inhibit HBV replication by decreasing the serum sE-selectin content,which may lead to an enhanced immune function.
出处
《临床肝胆病杂志》
CAS
2012年第11期839-840,844,共3页
Journal of Clinical Hepatology
